I agree that this site is using cookies. You can find further informations here.
X
Trněný, Marek
276  results:
Search for persons X
?
1

Blockage of BCL-XL overcomes venetoclax resistance across B..:

Dolnikova, Alexandra ; Kazantsev, Dmitry ; Klanova, Magdalena...
Blood Advances.  8 (2024)  13 - p. 3532-3543 , 2024
Link: https://doi.org/10.1182/..
 
?
2

High Complete Metabolic Response Rates with Epcoritamab SC ..:

Brody, Joshua ; Jørgensen, Judit ; Belada, David...
Transplantation and Cellular Therapy.  30 (2024)  2 - p. S357 , 2024
Link: https://doi.org/10.1016/..
 
?
3

Long-term treatment with rilzabrutinib in patients with imm..:

Kuter, David J. ; Mayer, Jiri ; Efraim, Merlin...
Blood Advances.  8 (2024)  7 - p. 1715-1724 , 2024
Link: https://doi.org/10.1182/..
 
?
4

Hematopoietic stem cell transplantation for DLBCL: a report..:

Berning, Philipp ; Fekom, Mathilde ; Ngoya, Maud...
Blood Cancer Journal.  14 (2024)  1 - p. , 2024
Link: https://doi.org/10.1038/..
 
?
5

Biomarker analysis of the ASPEN study comparing zanubrutini..:

Tam, Constantine S. ; Opat, Stephen ; D'Sa, Shirley...
Blood Advances.  8 (2024)  7 - p. 1639-1650 , 2024
Link: https://doi.org/10.1182/..
 
?
6

Ibrutinib combined with immunochemotherapy with or without ..:

Dreyling, Martin ; Doorduijn, Jeanette ; Giné, Eva...
The Lancet.  403 (2024)  10441 - p. 2293-2306 , 2024
Link: https://doi.org/10.1016/..
 
?
7

Cyclin dependent kinase 4/6 inhibitor palbociclib synergize..:

Malarikova, Diana ; Jorda, Radek ; Kupcova, Kristyna...
Experimental Hematology & Oncology.  13 (2024)  1 - p. , 2024
Link: https://doi.org/10.1186/..
 
?
8

P1080: ZANUBRUTINIB PLUS OBINUTUZUMAB VERSUS OBINUTUZUMAB I..:

Trotman, Judith ; Luigi Zinzani, Pier ; Mayer, Jiri...
HemaSphere.  7 (2023)  S3 - p. e2687131 , 2023
Link: https://doi.org/10.1097/..
 
?
9

P639: ZANUBRUTINIB (ZANU) VS BENDAMUSTINE + RITUXIMAB (BR) ..:

Munir, Talha ; Shadman, Mazyar ; Robak, Tadeusz...
HemaSphere.  7 (2023)  S3 - p. e15364af , 2023
Link: https://doi.org/10.1097/..
 
?
10

Parsaclisib, a PI3Kδ inhibitor, in relapsed and refractory ..:

Trněný, Marek ; Avigdor, Abraham ; McKinney, Matthew S....
eClinicalMedicine.  63 (2023)  - p. 102130 , 2023
Link: https://doi.org/10.1016/..
 
?
11

P1240: MICROBIOME DIVERSITY IN PATIENTS WITH LYMPHOMA:

Dlouha, Lucie ; Tenglerova, Marketa ; Rehakova, Johana...
HemaSphere.  7 (2023)  S3 - p. e92993bd , 2023
Link: https://doi.org/10.1097/..
 
?
12

Characterization of the input material quality for the prod..:

Štach, Martin ; Pytlík, Robert ; Šmilauerová, Kristýna...
Pathology and Oncology Research.  29 (2023)  - p. , 2023
Link: https://doi.org/10.3389/..
 
?
13

MCL-467 Glofitamab Monotherapy Induces High Complete Respon..:

Phillips, Tycel ; Dickinson, Michael ; Morschhauser, Franck...
Clinical Lymphoma Myeloma and Leukemia.  23 (2023)  - p. S462 , 2023
Link: https://doi.org/10.1016/..
 
?
14

Safety and efficacy of tafasitamab with or without lenalido..:

Belada, David ; Kopeckova, Katerina ; Bergua Burgues, Juan Miguel...
Blood.  142 (2023)  16 - p. 1348-1358 , 2023
Link: https://doi.org/10.1182/..
 
?
15

A comparison of the prognostic performance of the Lugano 20..:

Kostakoglu, Lale ; Martelli, Maurizio ; Sehn, Laurie H....
eJHaem.  4 (2023)  4 - p. 1042-1051 , 2023
Link: https://doi.org/10.1002/..
 
1-15